Haematuria; a late complication of TURP?

Bowden, EA; Foley, S.J.

doi:10.1038/sj.pcan.4500507

Cited by 4 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on their findings, they considered hematuria as a late complication of TURP. [ 21 ] Similarly, Wang et al . noted that the primary reason for admission in patients with recurrent BPH (post-TURP) was severe hematuria (44.4%).…”

Section: Discussionmentioning

confidence: 99%

Does prior transurethral resection of prostate have a negative impact on the outcome of holmium laser enucleation of prostate? Results from a prospective comparative study

et al. 2022

View full text Add to dashboard Cite

Objectives To prospectively evaluate safety and efficacy of holmium laser enucleation of prostate (HoLEP) for surgical treatment of recurrent symptoms due to prostatomegaly after prior transurethral resection of prostate (TURP). Materials and Methods: We prospectively evaluated 43 patients with a history of TURP who underwent HoLEP (study group). Patients in chronological order who underwent HoLEP without prior TURP were included in the control group. We hypothesized that prior TURP would increase technical difficulties, thereby leading to a reduction in procedure efficiency by 25%. Patients’ demographic, intraoperative, and postoperative data were compared, and statistical analysis was performed. Results: Demographic data in both groups were comparable. The average interval between past TURP and HoLEP was 4.22 years. There was no difficulty in identifying the dissection plane in the study group and the difference in the procedure efficiency between the study and the control groups were statistically insignificant (0.75 ± 0.31 g/min-study group vs. 0.69 ± 0.36 g/min-control group; P = 0.665). The intraoperative parameters and postoperative outcomes were comparable in both groups. Conclusions: Prior TURP does not negatively impact the outcome of HoLEP in treating symptomatic recurrence for enlarged prostate after initial TURP.

show abstract

Section: Discussionmentioning

confidence: 99%

Does prior transurethral resection of prostate have a negative impact on the outcome of holmium laser enucleation of prostate? Results from a prospective comparative study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For the 42 studies , quality was 'good' in eight [20,21,[24][25][26]36,53,57], 'fair' in 22 [23,27,29,[31][32][33]37,38,40,41,43,47,49,51,52,[54][55][56][58][59][60][61] and 'poor' in 12 studies [22,28,30,34,35,39,42,[44][45][46]48,50]. As studies rated of 'good' quality were deemed to have low bias, we wanted to investigate the prostate cancer prevalence specifically for these studies [20,21,[24][25][26]36,53,57].…”

Section: Study Qualitymentioning

confidence: 99%

“…Almost all included studies reported performing either cystoscopy or imaging, or both, but as a DRE and PSA test are the initial clinical tests for the evaluation of prostate cancer, we enumerated the prostate cancer prevalence for studies that clearly described performing a DRE or PSA test on all included men (n = 11) [21][22][23][24]26,29,32,33,38,44,58]. In these 11 studies, the pooled prevalence (95% CI) of prostate cancer was 3.1% (1.9-4.5%; Fig.…”

Section: Diagnostic Approach For Prostate Cancermentioning

confidence: 99%

“…To determine the significance of the organisation of haematuria diagnostic evaluation, we enumerated the prostate cancer prevalence for studies reporting results from specialised haematuria clinics (n = 12) [21,23,[25][26][27]29,38,[54][55][56][57][58]. In the remaining studies (n = 30), haematuria was handled in general urology departments, other hospital departments, or by GPs, and in some studies the setup was not described.…”

Section: Attending a Haematuria Clinicmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of prostate cancer in men with haematuria: a systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

To investigate the prevalence of prostate cancer in men attending evaluation for haematuria, as this could help healthcare providers to determine whether men with haematuria should have prostate examinations performed. MethodsThe study was performed according to a pre-specified protocol uploaded to the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022299383). A systematic search of MEDLINE, Ovid and Google Scholar was performed in December 2021. Two independent researchers evaluated all titles, available abstracts, and full texts. We included studies on adult men (aged ≥18 years) describing haematuria and prostate cancer. ResultsWe screened 4252 titles and abstracts when available and assessed 350 studies in full text. In total, 65 studies were included and 42 was summarised in a meta-analysis. In total, 18 752 men with haematuria were included, and the pooled prevalence (95% confidence interval [CI]) of prostate cancer was 3.0% (2.0-4.1%). In men with macroscopic haematuria, the pooled prevalence (95% CI) of prostate cancer was 5.9% (2.9-9.9%; n = 265/5373). In men with microscopic haematuria, the pooled prevalence (95% CI) of prostate cancer was 1.4% (0.8-2.2%; n = 71/6642). ConclusionOur findings indicate that the prevalence of prostate cancer is considerable in men attending evaluation for haematuria. Therefore, digital rectal examination and prostate-specific antigen measurement should become a standard procedure for all men with haematuria, especially for men with macroscopic haematuria.

show abstract

“…The tissue on the cut surface forms an eschar, whose organisational structure is fuzzy, leading to injury even perforation of the surgical capsule. In addition, the eschar may bring about secondary haemorrhage (15) after shedding and repeated haematuria after the operation. And the high temperature of TURP can cause urethral burn and postoperative urethral stricture (16)(17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

The Design and Rationale of a Multicentre Randomised Controlled Trial Comparing Transperineal Percutaneous Laser Ablation With Transurethral Resection of the Prostate for Treating Benign Prostatic Hyperplasia

Zhang

Guo

et al. 2021

Front. Surg.

View full text Add to dashboard Cite

Background: Transurethral resection of the prostate (TURP) is regarded as the “gold standard” for the treatment of benign prostatic hyperplasia (BPH) in elderly men. However, ~15% of patients who had undergone TURP had intraoperative and postoperative complications, such as bleeding, urinary incontinence and urethral stricture. Transperineal percutaneous laser ablation (TPLA) is a method that places the optical fibre directly into the prostate with the guidance of ultrasound imaging, and the percutaneous transperineal approach is performed distal to the urethra and rectum to protect these structures and reduce urethral or postoperative infection. Several studies on TPLA for BPH treatment have been reported recently; however, high-quality randomised controlled trial (RCT) to evaluate its efficacy, safety, and long-term follow up remain absent.Methods: This study is a multicentre, open-label RCT to assess the efficacy and safety of TPLA vs. TURP to treat BPH. We hypothesise that the TPLA has non-inferior efficacy to TURP in the International Prostate Symptom Score (IPSS) at 3 months changing from the baseline and lower incidence of post-surgery complications. One hundred and fourteen patients with BPH will be recruited at 19 sites and randomly assigned at 1:1 to TPLA or TURP groups. The patients will be followed up at 1, 3, 6, 12, and 24 months after the procedure.Discussion: The study will be the first multicentre clinical trial including 16 participating centres in China, Italy, Switzerland, and Poland with relatively large sample size 114. By comprehensively compare the safety and efficacy of TPLA with TURP in patients with BPH, especially concerning the improvement of lower urinary tract symptoms (LUTS) and complication incidence, the study will help to illustrate the clinical value of TPLA and provide a beneficial alternative treatment for BPH patients.Clinical Trial Registration: The study has been registered on Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier [ChiCTR1900022739].

show abstract

Haematuria; a late complication of TURP?

Cited by 4 publications

References 9 publications

Does prior transurethral resection of prostate have a negative impact on the outcome of holmium laser enucleation of prostate? Results from a prospective comparative study

Does prior transurethral resection of prostate have a negative impact on the outcome of holmium laser enucleation of prostate? Results from a prospective comparative study

Prevalence of prostate cancer in men with haematuria: a systematic review and meta‐analysis

The Design and Rationale of a Multicentre Randomised Controlled Trial Comparing Transperineal Percutaneous Laser Ablation With Transurethral Resection of the Prostate for Treating Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About